Therapy with any azole antifungals (e.g., itraconazole, ketaconazole, voriconazole) at the time of enrollment
Prior systemic treatment with an azole drug within four weeks of cycle  day .
Subject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.
Patient is receiving any azole.
Known hypersensitivity or other serious adverse reaction to any azole antifungal therapy or to any other ingredient of the study medication used.
Prior systemic treatment with an azole anti-fungal drug (e.g. fluconazole, itraconazole) within  weeks of cycle , day 
Prior systemic treatment with an azole drug within four weeks of screening visit
Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within  weeks of cycle , day 
Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within  weeks of cycle , day 
Prior systemic treatment with an azole drug (fluconazole, itraconazole) within  weeks of cycle  day .
Prior systemic treatment with an azole drug within two weeks of start of treatment
Patients with a history of echinocandin or azole hypersensitivity are not eligible
Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents
Clinically significant elevation of liver function tests prior to the first day of dosing (FDD) that at the discretion of the treating physician would preclude the administration of an azole antifungal
Has a history of anaphylaxis attributed to the azole class of antifungal agents
Oral ketoconazole or other azole antifungals
